Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Vera Therapeutics (VERA) has shared an update.
Vera Therapeutics has appointed David Johnson, a seasoned biopharmaceutical executive with over two decades of industry experience, as their new Chief Operating Officer starting July 1, 2024. Johnson brings a wealth of knowledge from his previous roles, including his time as Chief Commercial Officer at Global Blood Therapeutics and various leadership positions at Gilead Sciences, where he successfully launched multiple drugs for liver diseases and HIV. As part of his compensation, Johnson will receive a $500,000 annual salary, eligibility for a 40% performance bonus, and stock options that vest over four years, with additional benefits in the event of a qualifying termination.
Learn more about VERA stock on TipRanks’ Stock Analysis page.
